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Purpose: Based on the vascular theory of glaucoma pathogenesis, we wanted to evaluate the effect of Ginkgo bilo-
ba extract (GBE) on peripapillary blood flow in patients with normal tension glaucoma (NTG).
Methods: Thirty patients with NTG were randomly placed in the GBE-treated or control groups. The GBE-treated 
group received 80 mg GBE orally, twice a day for four weeks, and the control group received a placebo twice a 
day for four weeks. Complete ocular examinations including visual field, Heidelberg retina flowmeter, and systemic 
examinations were performed on the first study day and on the day treatment was completed. 
Results: After GBE treatment, the mean blood flow, volume, and velocity increased at almost all points, and there 
was a statistically significant increase in blood flow at almost all points, in comparison to the placebo. Blood volume 
significantly increased only in the superior nasal and superior temporal neuroretinal rim areas. GBE also significantly 
increased blood velocity in areas of the inferior temporal neuroretinal rim and superior temporal peripapillary area.
Conclusions: GBE administration appears to have desirable effect on ocular blood flow in NTG patients. 
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Although the pathogenesis of glaucoma remains obscure, 
both a mechanical theory (intraocular pressure [IOP] causes 
structural damage to the nerve head) and vascular theory 
(tissue ischemia from impaired blood flow causes glaucoma-
tous damage) have been proposed [1,2]. Recently, many re-
ports support the vascular theory, which suggests that vas-
cular factors may be involved in the pathogenesis of 
glaucoma. These factors include systemic hypotension, vas-
ospasm (migraine, Raynaud’s disease), cardiovascular dis-
ease, autoimmune disease, hemorrhagic abnormalities and 
cerebral microvascular ischemia [3].
Normal tension glaucoma (NTG) is a form of glaucoma in 
which optic nerve damage and glaucomatous visual field loss 
occurs without the IOP exceeding the normal range. 
Treatment of glaucoma has almost always focused on low-
ering the IOP, but some patients with NTG continue to suffer 
a visual field defect despite sufficient control of IOP. 
Therefore, pharmacologic treatment of the vascular mecha-
nism underlying glaucoma should be emphasized in NTG 
patients. 
Ginkgo biloba extract (GBE) consists of flavonoid glyco-
sides, terpene lactone (ginkgolides), and other organic acids 
[4]. GBE is widely used in treating vascular diseases such as 
peripheral circulation diseases and cerebral insufficiency [5], 
because of its favorable effect on blood circulation. Flavonoids 
can dilate blood vessels by increasing the release of endothe-
lium-derived relaxing factor and prostacyclin (PGI2) from 
vascular endothelial cells, and decrease blood viscosity by 
antagonizing platelet activating factor [6]. Moreover, fla-
vonoid glycosides act as antioxidants by scavenging free rad-
icals [7]. These properties support the therapeutic value of 
GBE in treating NTG.
There have been reports on the effect of GBE on ocular 
blood flow in healthy individuals; Chung et al. [8] reported 
that GBE significantly increased end diastolic flow velocity 
in the ophthalmic artery of healthy volunteers. In Korea, Lee 
et al. [9] confirmed that GBE increases microcircular blood 
velocity, flow, and volume in healthy individuals.
However, there has been little investigation into the effect 
of GBE on ocular blood flow in NTG patients. We aimed to 
evaluate the short-term effects of GBE on peripapillary reti-
nal blood flow in patients with NTG.
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Fig. 1. Schematic diagram showing locations where perfusion pe-
rimeters were measured. 1, Superior nasal peripapillary retina area; 
2, inferior nasal peripapillary retina area; 3, superior nasal neuro-
retinal rim area; 4, inferior nasal neuroretinal rim area; 5, superior 
optic cup area; 6, inferior optic cup area; 7, superior temporal neu-
roretinal rim area; 8, inferior temporal neuroretinal rim area; 9, su-
perior temporal peripapillary retina area; 10, inferior temporal peri-
papillary retina area.
Materials and Methods
Patients
For this trial, we recruited 30 patients who were diagnosed 
as having NTG at Gangnam Severance Hospital between 
January 2003 and December 2004. The study followed the 
tenets of the Declaration of Helsinki and was approved by the 
local Institutional Review Board. All patients provided in-
formed consent.
The eligibility criteria were as follows: 1) patients between 
the ages of 18 and 80, 2) patients with unilateral or bilateral 
NTG with glaucomatous visual field defect and/or abnormal 
excavation of optic nerve head (ONH) ratio, IOP < 21 mmHg 
with open angle, 3) patients with no medical history of glauco-
ma, and in cases of patients taking medications with any effect 
on blood flow, no change of dose and direction of medication for 
at least two months before trial, and no cessation of medication 
more than two weeks before the trial (e.g. calcium channel 
blocker, ACE inhibitor, angiotensin II receptor blocker, β- 
blocker), 4) patients with no known diabetes, and 5) patients 
who had not taken vitamin compounds for more than one month. 
The exclusion criteria included patients with closed or 
shallow angle glaucoma, contact lens wearers, history of oc-
ular surgery or Argon laser trabeculoplasty, history of ocular 
inflammation or infection in the 12 weeks before the trial, hy-
persensitivity to ginkgo extracts, pregnant or breast-feeding 
women, alcoholism, or addiction to medications.
Experimental design
This study followed a randomized, double-masked, place-
bo-controlled clinical trial design. The 30 patients were ran-
domly assigned to one of the two groups (GBE-treated or 
placebo). Eligible participants were randomly allocated to 
two groups a using blocked randomization (block size = 10) 
list produced in advanced and prescriptions were prepared. 
The prescribed medication was dispensed at the clinic imme-
diately after he or she consented to this trial. Clinicians and 
patients were not aware of the treatment being administered.
The GBE-treated study group (15 patients) received 80 mg 
GBE (flavonoid glycosides 19.2 mg) orally, two times a day 
for four weeks, and the control group (15 patients) received 
the placebo orally, two times a day for four weeks. Participants 
were asked to maintain their dosages of any medications that 
could influence blood flow during the study period.
Complete ocular examinations including visual field, 
Heidelberg retina flowmeter (HRF; Heidelberg Engineering, 
Heidelberg, Germany) and systemic examinations, were per-
formed on the first study day and upon completion of the 
treatment. 
Blood flow measurement
Blood flow measurements were made by confocal scan-
ning laser Doppler flowmetry (SLDF) [10] using the HRF. 
We obtained two-dimensional visualization of the retina and 
ONH microcirculation with blood flow parameters including 
flow, volume, and velocity with HRF.
The two-dimensional planes measured by HRF were scan-
ned repeatedly in a linear fashion. Each line had 256 pixels 
(10 μm) and was scanned 128 times with a line-sampling rate 
of 4,000 Hz. In total, 64 vertical lines were measured in this 
process and the total data acquisition time was 2.048 seconds. 
After completion of retinal perfusion maps, mean flow, vol-
ume, and velocity can be calculated in any of the retinal 
areas. Flow describes the distance gone by all moving cells 
inside the sample volume per unit time. Volume is propor-
tional to the mean number of photon collisions with moving 
cells in a sample volume of the tissue, and velocity can be 
calculated from the equation of ‘velocity = flow / volume’ [10].
In this study, all measurements were made without pupil-
lary dilation. The areas measured were 10° × 2.5° around the 
disc. Three separate perfusion images were acquired for each 
eye by the same experienced optometrist. Perfusion parame-
ters (volume, flow, velocity) were measured at two nasal per-
ipapillary retina areas, two nasal neuroretinal rim areas, two 
optic cup areas, two temporal neuroretinal rim areas, and two 
temporal peripapillary retina areas with a size of 10 × 10 pix-
els (Fig. 1). The averages of the measurements from the three 
images were used for statistical analysis.
Statistical analysis
Baseline demographic and clinical parameters were com-
pared between treatment groups using Fisher’s exact test for 
categorical variables and Wilcoxon rank sum test for con-
tinuous variables. Between-group comparisons before and 
after medication were performed using Wilcoxon rank sum 
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Table 1. Characteristics of all patients studied
Comedication 
variables
GBE-treated 
%
Placebo 
% p-value
no. no.
Age <65 11 73.3 11 73.3 1.00*
≥65  4 26.7  4 26.7
Gender Male  7 46.7  4 26.7 0.26*
Female  8 53.3 11 73.3
Allergy No 12 80.0 14 93.3 0.60*
Yes  3 20.0  1 6.7
Operation No 13 86.7 11 73.3 0.65*
Yes  2 13.3  4 26.7
Past history No  1  6.7  0  0.0 1.00*
Yes 14 93.3 15 100.0
Medication history No  2 13.3  2 13.3 1.00*
Yes 13 86.7 13 86.7
Comedication No  8 53.3  7 46.7 0.72*
Yes  7 46.7  8 53.3
Baseline pre_IOPS 12.6 ± 3.25 13.1 ± 1.77 0.88†
Baseline pre_IOPD 14.0 ± 2.85 13.9 ± 1.87 0.88†
Weight 59.0 ± 5.95 60.1 ± 6.83 0.98†
Height 162.4 ± 6.19 160.6 ± 6.65 0.52†
GBE = Ginkgo biloba extract; IOPS = intraocular pressure of left eye; IOPD = intraocular pressure of right eye. 
*Fisher's exact test; †Wilcoxon rank sum test.
Table 2. Visual field indices and IOP before and after medication
Variables Baseline GBE-treated Baseline Placebo p-value
IOP 12.6 12.4 13.1 13.0 0.67
MD -10.27   -9.52 -11.55 -10.76 0.62
CPSD    7.24    6.79   6.46   5.58 0.97
IOP = intraocular pressure; GBE = Ginkgo biloba extract; MD = mean deviation and corrected pattern standard deviation; CPSD = 
corrected pattern standard deviation.
test for study endpoints (peripapillary blood flow measure-
ments).
In addition, paired-t tests were utilized to compare differ-
ences before and after medication with baseline values with-
in treatment groups. A p-value less than 0.05 was accepted as 
statistically significant.
Results
 The baseline characteristics are listed in Table 1. No sig-
nificant differences in demographics were recorded between 
the two groups. All patients completed the trial and no ocular 
or systemic side effects were reported in any patients during 
the trial. No significant modification of IOP or reduction in 
the mean deviation (MD) and corrected pattern standard de-
viation (CPSD) values were noted after GBE medication 
(Table 2). Tables 3, 4, and 5 show the effect of GBE and place-
bo on ocular blood flow, volume, and velocity, respectively. 
After GBE treatment, the mean value of blood flow, volume, 
and velocity increased at almost all points. A statistically sig-
nificant increase in blood flow in response to GBE compared 
with placebo was noted at all points, except for the superior 
nasal peripapillary area (point 1) and optic cup areas (points 
5, 6) (Table 3). Blood volume significantly increased after in-
take of GBE compared to placebo only in the superior nasal 
and superior temporal neuroretinal rim areas (points 3, 7) 
(Table 4). GBE also significantly increased blood velocity 
compared with placebo in the inferior temporal neuroretinal 
rim (point 8) and superior temporal peripapillary area (point 
9) (Table 5).
Discussion
During the last 150 years, glaucoma has been considered 
to be a disease resulting from increased IOP, and IOP-low-
ering therapy is the most common intervention available for 
treatment of glaucoma. However, with recognition of the fact 
that marked IOP reduction cannot stop disease progression in 
all patients, the principles of treating glaucoma are changing. 
Elevated IOP is not the disease itself, but rather a risk factor 
for glaucoma [11,12].
Non-IOP-dependent risk factors for glaucomatous optic 
nerve damage have become an area of increasingly active 
investigation. Specifically, vascular components seem to 
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Table 3. Blood flow measurements on Heidelberg retina flowmeter before and after medication
Flow measure point Point
GBE-treated group Placebo
p-value
Before After Before After
Nasal peripapillary retina area 1 356.8 381.8 297.4 307.0  0.20
2 330.8 351.6 302.3 304.0  0.02*
Nasal neuroretinal rim area 3 383.7 447.8 433.9 396.7 <0.01*
4 399.6 460.7 395.4 394.7   0.03*
Optic cup area 5 244.7 276.9 258.2 261.9  0.07
6 249.1 285.4 258.2 289.3  0.21
Temporal neuroretinal rim area 7 288.5 342.8 320.7 308.2 <0.01*
8 266.3 317.8 300.6 299.2 <0.01*
Temporal peripapillary retina area 9 338.7 366.1 344.6 341.0 <0.01*
10 351.0 396.3 330.7 338.1 <0.01*
GBE = Ginkgo biloba extract.
*Wilcoxon rank sum test.
Table 4. Blood volume measurements on Heidelberg retina flowmeter before and after medication
Volume measure point Point
GBE-treated group Placebo group
p-value
Before After Before After
Nasal peripapillary retina area 1 20.6 22.3 16.1 17.7 0.84
2 17.7 20.7 16.1 17.9 0.41
Nasal neuroretinal rim area 3 14.2 18.6 15.6 15.9 0.03*
4 15.0 16.5 13.5 14.8 0.58
Optic cup area 5 13.3 16.1 12.5 14.2 0.30
6 13.7 16.9 12.2 14.3 0.56
Temporal neuroretinal rim area 7 12.0 16.7 14.2 14.5  0.01*
8 11.8 16.0 13.7 15.2 0.25
Temporal peripapillary retina area 9 20.6 23.0 19.9 21.9 0.65
10 20.5 24.8 18.9 21.3 0.28
GBE = Ginkgo biloba extract.
*Wilcoxon rank sum test.
Table 5. Blood velocity measurements on Heidelberg retina flowmeter before and after medication
Velocity measure point Point
GBE-treated group Placebo group
p-value
Before After Before After
Nasal peripapillary retina area 1 1.2 1.3 1.0 1.1 0.63
2 1.2 1.2 1.1 1.1 0.15
Nasal neuroretinal rim area 3 1.4 1.5 1.5 1.4 0.10
4 1.4 1.5 1.4 1.4 0.16
Optic cup area 5 0.8 1.0 0.9 0.9 0.12
6 0.9 1.0 0.9 1.0 0.43
Temporal neuroretinal rim area 7 1.0 1.1 1.1 1.1 0.07
8 0.9 1.1 1.1 1.1  0.03*
Temporal peripapillary retina area 9 1.2 1.3 1.2 1.8 <0.01*
10 1.2 1.3 1.1 1.2 0.06
GBE = Ginkgo biloba extract.
*Wilcoxon rank sum test.
have an important role in the genesis and progression of 
NTG. Lee et al. [13] reported that the NTG patients had sig-
nificantly decreased blood volume, flow, and velocity in the 
nasal neuroretinal rim and temporal peripapillary retina com-
pared with normal individuals. Moreover, there were statisti-
cally significant decreases in peak systolic and diastolic ve-
locities of the ophthalmic artery in normal-tension glaucoma 
compared to primary open angle glaucoma [14]. These re-
sults imply that a local vascular factor might be related to the 
development of normal-tension glaucoma.
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The ONH has a very characteristic blood supply. The su-
perficial layer of the ONH is supplied by small branches of 
the central retinal artery. The prelaminar region receives its 
blood supply via branches from recurrent choroid arterioles 
and the short posterior ciliary arteries. Diffusion from the 
surrounding choroid is also possible. The circulation to the 
optic nerve is autoregulated by endothelial, neural, and myo-
genic mechanisms [15]. Autoregulation refers to the main-
tenance of constant blood and nutrient supplies by local vas-
cular constriction or dilation of vessels in response to perfu-
sion pressure changes [16]. Dysregulation of ocular vessels 
can contribute to progression of glaucoma and research has 
shown that certain systemic medications can be used for reg-
ulation of vascular dysfunction in glaucoma patients. 
Calcium channel blockers can reduce ocular vasospasm in 
certain glaucoma patients and improve visual field defects by 
reducing the effect of increased endothelin-1 levels [17,18]. 
Nitric oxide is another vasoactive molecule that can induce a 
vasodilatory response. One study demonstrated that a sys-
temic nitroglycerin preparation can induce a protective effect 
in glaucoma patients who are taking the medication for an-
other reason [19].
GBE also has many properties that should be beneficial in 
treating non-IOP-dependent risk factors related not only to 
ocular hemodynamics, but also to neuroprotective action. 
Neuroprotection refers to the post-injury protection of neu-
rons that are initially undamaged or only marginally dam-
aged by a particular insult [3]. The ultimate object of neuro-
protection in glaucoma patients is to prevent retinal ganglion 
cell death, and this can be achieved by blocking secondary 
degeneration. Secondary degeneration refers to the spread of 
degeneration to apparently healthy neurons that are at risk 
from toxic stimuli (glutamate, calcium, nitric oxide, free rad-
ical) released by damaged cells [20-22]. Several animal mod-
els have confirmed that the neuroprotective effect of GBE 
prevents secondary degeneration [23-25].
Many researchers have studied the effects of GBE on the 
visual field. Quaranta et el. [26] evaluated the effect of GBE 
on pre-existing visual field damage in patients with NTG, 
and recorded significant improvement in visual field indices 
(MD, CPSD) after GBE treatment. Ha and Rho [27] also as-
sessed the effect of oral GBE on the visual field in patients 
with NTG, and improvement in the visual field through MD, 
CPSD, and GHT cluster mean threshold was obtained in a 
NTG patient during at least four years of treatment. In the 
present study, no significant improvement in MD or CPSD 
was noted after GBE treatment. However, we employed only 
one measure of visual field examination before and after 
medication, and we did not consider the reliability index. 
Moreover, the follow-up period (four weeks) was too short to 
influence the visual field. Therefore, it is likely that GBE has 
beneficial effect on visual field.
Although the mean value of blood flow, volume, and ve-
locity increased at almost all points in this study, no sig-
nificant increment was noted at the optic cup area. Lamina 
cribrosa has blood supply from centripetal branches of the 
short posterior ciliary artery. In addition, blood vessels lie in 
the fibrous septa and form a dense capillary plexus that 
makes this part of the ONH a highly vascular structure. The 
area that has already sufficient blood supply may have mini-
mal effect of GBE. Therefore, we thought that GBE can im-
prove blood circulation more effectively in the area of de-
creased blood supply. 
A limitation of this study is its short-term follow-up period. 
We cannot comment on the long-term effects of GBE admin-
istration, because of the limited duration (one month) of our 
study. Therefore, further study is required to investigate of 
the duration of the effect and optimal administration sched-
ule for GBE treatment for NTG patients.
Another limitation of this study is that the reproducibility 
of HRF measurements in these NTG patients was not 
obtained. To evaluate reproducibility, the coefficient of var-
iation of the three measurements calculated by SLDF is gen-
erally used [28,29]. Although we did not calculate reproduci-
bility, blood flow measurements were obtained several times 
for each eye at each session by the same experienced inves-
tigator to acquire good-quality images. Moreover, the reli-
ability of HRF to measure ocular blood flow has been pub-
lished, and HRF allows reproducible blood perfusion meas-
urements of retinal and lamina cribrosa areas when a target 
square of 10 × 10 pixels is used [10].
This article is the first prospective study on the effect of 
GBE on ocular blood flow in NTG. There have not been any 
previously reported studies on this subject. In this study, 
GBE administration increased peripapillary blood flow, vol-
ume, and velocity, although some of these increases were not 
statistically significant compared with placebo and the loca-
tions differed in terms of the statistically significant increases 
in blood flow, volume, and velocity.
In conclusion, the results of this study demonstrate that 
GBE administration can produce desirable effects on peri-
papillary blood circulation, suggesting that GBE is a benefi-
cial systemic treatment for NTG patients. 
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